JP2015501285A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501285A5
JP2015501285A5 JP2014526247A JP2014526247A JP2015501285A5 JP 2015501285 A5 JP2015501285 A5 JP 2015501285A5 JP 2014526247 A JP2014526247 A JP 2014526247A JP 2014526247 A JP2014526247 A JP 2014526247A JP 2015501285 A5 JP2015501285 A5 JP 2015501285A5
Authority
JP
Japan
Prior art keywords
seq
αvβ8
antibody
cdr sequences
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501285A (ja
JP6093360B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/051373 external-priority patent/WO2013026004A2/en
Publication of JP2015501285A publication Critical patent/JP2015501285A/ja
Publication of JP2015501285A5 publication Critical patent/JP2015501285A5/ja
Application granted granted Critical
Publication of JP6093360B2 publication Critical patent/JP6093360B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526247A 2011-08-17 2012-08-17 インテグリンα−vβ−8と結合する抗体 Expired - Fee Related JP6093360B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161524708P 2011-08-17 2011-08-17
US61/524,708 2011-08-17
US201261646111P 2012-05-11 2012-05-11
US61/646,111 2012-05-11
PCT/US2012/051373 WO2013026004A2 (en) 2011-08-17 2012-08-17 Antibodies that bind integrin alpha-v beta-8

Publications (3)

Publication Number Publication Date
JP2015501285A JP2015501285A (ja) 2015-01-15
JP2015501285A5 true JP2015501285A5 (enExample) 2015-10-08
JP6093360B2 JP6093360B2 (ja) 2017-03-08

Family

ID=47715714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526247A Expired - Fee Related JP6093360B2 (ja) 2011-08-17 2012-08-17 インテグリンα−vβ−8と結合する抗体

Country Status (13)

Country Link
US (1) US9492569B2 (enExample)
EP (1) EP2744823B1 (enExample)
JP (1) JP6093360B2 (enExample)
KR (1) KR102010098B1 (enExample)
CN (1) CN103857696B (enExample)
AU (1) AU2012296362B2 (enExample)
BR (1) BR112014003501B1 (enExample)
CA (1) CA2846240C (enExample)
ES (1) ES2643397T3 (enExample)
MX (1) MX350335B (enExample)
RU (1) RU2614252C2 (enExample)
SG (1) SG2014014237A (enExample)
WO (1) WO2013026004A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
SG11201509982UA (enExample) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
PT3157561T (pt) * 2014-06-17 2020-03-25 Univ California Anticorpos contra alfa-v beta-8 melhorados
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
US10954304B2 (en) 2016-09-29 2021-03-23 The Regents Of The University Of California Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
JP7370252B2 (ja) * 2017-05-30 2023-10-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 神経炎症性疾患の治療
BR112021004287A2 (pt) * 2018-09-07 2021-08-03 Pfizer Inc. anticorpos anti-avss8 e composições e usos dos mesmos
WO2020102422A1 (en) * 2018-11-14 2020-05-22 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
TWI854088B (zh) * 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αvβ8整聯蛋白抗體
CN120225559A (zh) * 2022-09-12 2025-06-27 国家健康与医学研究院 新型抗itgb8抗体及其用途
WO2024206788A1 (en) * 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024258908A1 (en) * 2023-06-12 2024-12-19 University Of Washington De novo designed alpha (v) beta (8) integrin selective minibinder
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0575554A1 (en) 1991-03-14 1993-12-29 Genentech, Inc. Novel beta integrin subunit
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7803553B2 (en) * 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
EP3476861A1 (en) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
WO2010022737A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Anti-cd5 antibodies
SG178348A1 (en) * 2009-08-19 2012-03-29 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody

Similar Documents

Publication Publication Date Title
JP2015501285A5 (enExample)
RU2014109928A (ru) Антитела, которые связывают интегрин альфа-v бета-8
JP2013520173A5 (enExample)
AR126555A2 (es) Anticuerpos de oncostatina m humana y métodos de uso
JP2012143232A5 (enExample)
JP2014530215A5 (enExample)
JP2018536393A5 (enExample)
JP2012254092A5 (enExample)
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
JP2012012402A5 (enExample)
JP2014500009A5 (enExample)
JP2013518903A5 (enExample)
JP2015535828A5 (enExample)
JP2014113150A5 (enExample)
JP2018504610A5 (enExample)
RU2015104760A (ru) Связывающие kir3dl2 агенты
JP2009518005A5 (enExample)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
JP2015521627A5 (enExample)
JP2018504105A5 (enExample)
JP2012021001A5 (enExample)
CA2818635C (en) Antibodies selective for cells presenting erbb2 at high density
JP2013531655A5 (enExample)
JP2013529183A5 (enExample)
JP2016537383A5 (enExample)